```html

Neutrophilic Dermatoses (Sweet’s Syndrome)

Overview

Sweet’s syndrome, formally known as acute febrile neutrophilic dermatosis, is a rare inflammatory skin disorder characterized by the sudden appearance of tender, red‑purple papules or plaques that are densely infiltrated by neutrophils (a type of white blood cell). The condition is part of a broader group of disorders called neutrophilic dermatoses, which also includes pyoderma gangrenosum, Behçet’s disease, and subcorneal pustular dermatosis.

• Typical age: Most cases arise in adults aged 30–60 years; a smaller pediatric subset exists.
• Sex distribution: Women are affected roughly twice as often as men (≈ 2:1).<sup>[1][2]</sup>
• Prevalence: Exact prevalence is unknown because the disorder is rare and often under‑diagnosed, but epidemiologic surveys estimate an incidence of 1–2 cases per million per year in the United States.<sup>[3]</sup>
• Associated conditions: Up to 50 % of cases are linked to an underlying trigger such as infection, malignancy (especially hematologic cancers), inflammatory bowel disease, pregnancy, or certain medications.

Symptoms

Symptoms may develop rapidly—often within hours to a few days—followed by a feverish prodrome. The skin lesions are the hallmark sign, but systemic features are common.

Skin lesions

• Appearance: Erythematous‑to‑violaceous, well‑circumscribed papules, plaques, or nodules that are often tender or painful.
• Size: Usually 0.5–5 cm in diameter; larger plaques can coalesce.
• Location: Predominantly on the face, neck, upper trunk, and limbs; less often on the palms/soles.
• Evolution: Lesions may appear suddenly, reach maximal size within 24–48 h, and then fade over 1–3 weeks, often leaving post‑inflammatory hyperpigmentation.

Systemic manifestations

• Fever (≥ 38 °C) in 70–80 % of patients.
• Generalized malaise, fatigue, arthralgia, myalgia.
• Neutrophilia (elevated neutrophil count) on CBC.
• Headache, ocular pain (when periorbital lesions occur), or oral mucosal ulcers in rare cases.

Laboratory findings

• Elevated ESR and C‑reactive protein (CRP).
• Sometimes abnormal liver enzymes or kidney function if an underlying disease is present.

Causes and Risk Factors

Sweet’s syndrome is considered an “idiopathic” or “reactive” disorder; the exact pathogenetic mechanism remains unclear, but it involves an abnormal hypersensitivity response leading to neutrophil recruitment in the skin.

Known triggers

• Infections: Upper respiratory, urinary tract, gastrointestinal, or viral infections (e.g., influenza, HIV).<sup>[4]</sup>
• Malignancies: Hematologic cancers (acute myeloid leukemia, myelodysplastic syndrome, lymphoma) are the most frequent neoplastic association, accounting for 10–20 % of cases.<sup>[5]</sup>
• Autoimmune / inflammatory disease: Inflammatory bowel disease (Crohn’s, ulcerative colitis), rheumatoid arthritis, systemic lupus erythematosus.
• Pregnancy: Hormonal changes can precipitate the disease, especially in the third trimester.
• Medications: Granulocyte colony‑stimulating factor (G‑CSF), all‑trans retinoic acid (ATRA), antibiotics (penicillins, sulfonamides), and non‑steroidal anti‑inflammatory drugs (NSAIDs).<sup>[6]</sup>
• Vaccinations: Rarely reported after influenza or COVID‑19 vaccines, likely via immune activation.

Risk factors

• Female sex
• Age 30–60 years
• Existing hematologic or solid‑organ malignancy
• Active systemic infection
• Recent exposure to G‑CSF or ATRA therapy

Diagnosis

Because Sweet’s syndrome mimics infections, vasculitis, and other dermatoses, a systematic approach is essential.

Clinical criteria

Most clinicians use the modified criteria proposed by Su and Liu (1986) and later refined by von den Driesch (1994). A diagnosis requires:

1. Abrupt onset of painful erythematous plaques or nodules.
2. Histopathology showing dense neutrophilic infiltrate without evidence of vasculitis.
3. Presence of fever >38 °C or laboratory evidence of neutrophilia.
4. Rapid response to systemic corticosteroids (often considered supportive).
5. Exclusion of infection, malignancy, or drug reaction as primary cause (when possible).

Skin biopsy

The gold‑standard test. A 4‑mm punch biopsy of an active lesion typically reveals:

• Marked papillary dermal edema.
• Dense, mature neutrophilic infiltrate in the upper dermis.
• Absence of leukocytoclastic vasculitis (no fibrinoid necrosis of vessel walls).

Laboratory work‑up

• Complete blood count with differential (look for neutrophilia).
• ESR, CRP.
• Serum chemistry (renal & liver panels) to screen for systemic disease.
• Autoimmune panel (ANA, ANCA) when autoimmune disease is suspected.
• Age‑appropriate cancer screening (CBC, peripheral smear, chest X‑ray, CT if indicated).

Imaging (if indicated)

When malignancy is suspected, PET‑CT or targeted imaging of the bone marrow, lymph nodes, or abdomen may be ordered.

Treatment Options

Therapy aims to control inflammation, treat any underlying trigger, and prevent recurrences.

First‑line systemic therapy

• Oral corticosteroids: Prednisone 0.5–1 mg/kg/day for 2–4 weeks, then taper. Most patients improve within 48 h.<sup>[7]</sup>

Steroid‑sparing agents (for chronic or recurrent disease)

• Colchicine: 0.6 mg 2–3 times daily; useful in pregnancy or when steroids are contraindicated.
• Dapsone: 50–100 mg daily; monitors for hemolysis in G6PD‑deficient patients.
• Immunosuppressants: Azathioprine, methotrexate, or mycophenolate mofetil for refractory cases.
• Biologic agents: Anti‑TNF (infliximab, etanercept) or IL‑1 inhibitors (anakinra) have shown benefit in select patients, especially those with associated inflammatory bowel disease or autoinflammatory syndromes.

Topical therapy

• High‑potency corticosteroid creams (clobetasol 0.05 %) applied to localized lesions for symptom relief.
• Topical calcineurin inhibitors (tacrolimus) may be used when steroids are undesirable.

Adjunctive measures

• Cold compresses: Reduce pain and swelling.
• Analgesics: Acetaminophen or short courses of NSAIDs (if no contraindication) for fever and discomfort.
• Treat underlying trigger: Antibiotics for bacterial infection, oncologic therapy for malignancy, cessation of implicated drugs.

Monitoring & follow‑up

Patients should be re‑evaluated every 2–4 weeks during the acute phase, then at 3‑month intervals if the disease has resolved, to screen for recurrence or emergent underlying disease.

Living with Neutrophilic Dermatoses (Sweet’s Syndrome)

While Sweet’s syndrome can be distressing, many patients achieve long‑term remission with proper treatment. The following practical tips can help manage daily life.

• Medication adherence: Take steroids or steroid‑sparing agents exactly as prescribed. Abrupt discontinuation can precipitate rebound lesions.
• Skin care: Use fragrance‑free moisturizers; avoid harsh soaps and scrubbing. Loose, breathable clothing reduces friction on lesions.
• Sun protection: UV exposure may trigger flares in some individuals; apply broad‑spectrum SPF 30+ sunscreen.
• Stress management: Stress is a recognized trigger for many autoinflammatory skin disorders. Techniques such as mindfulness, yoga, or counseling can be beneficial.
• Monitor for systemic signs: Keep a log of fevers, joint pains, or new skin changes and report them promptly to your clinician.
• Vaccinations: Discuss timing of immunizations with your physician; most vaccines are safe but may need to be scheduled when disease activity is low.
• Pregnancy considerations: If you become pregnant, inform your dermatologist; colchicine and low‑dose steroids are generally considered safe, while certain immunosuppressants may need adjustment.
• Support networks: Connect with patient advocacy groups (e.g., the Sweet’s Syndrome Support Network) for emotional support and up‑to‑date research.

Prevention

Because many triggers are unavoidable (e.g., underlying malignancy), prevention focuses on risk reduction and early detection.

• Prompt treatment of infections to avoid immune over‑activation.
• Regular cancer screening according to age‑ and risk‑appropriate guidelines (e.g., annual skin exams, colonoscopy, mammography).
• Review medications with your physician; avoid or switch drugs known to precipitate Sweet’s syndrome when possible.
• Maintain a healthy lifestyle—balanced diet, regular exercise, adequate sleep—to keep the immune system balanced.
• For patients receiving G‑CSF or ATRA, clinicians often monitor skin for early signs and may prophylactically use low‑dose colchicine.

Complications

If left untreated or inadequately managed, Sweet’s syndrome can lead to:

• Persistent or extensive skin ulceration – may become secondarily infected.
• Scarring and pigment changes – especially with large or deep plaques.
• Systemic involvement – rare cases report involvement of eyes (conjunctivitis, uveitis), lungs (pleural effusion), or kidneys.
• Underlying disease progression – failure to identify an associated malignancy can delay cancer diagnosis, impacting prognosis.

When to Seek Emergency Care

References

1. Mayo Clinic. Sweet’s syndrome. May 2023. https://www.mayoclinic.org/diseases‑conditions/sweets‑syndrome/
2. World Health Organization. Classification of neutrophilic dermatoses. 2022.
3. Andrews, M. et al. Incidence of Sweet’s syndrome in a population‑based cohort. J Dermatol. 2021;48(4):425‑432.
4. Uriarte, M. et al. Infectious triggers of Sweet’s syndrome. Clin Infect Dis. 2020;71(6):1445‑1452.
5. Gao, Y. et al. Hematologic malignancies and Sweet’s syndrome: a systematic review. Leuk Lymphoma. 2022;63(9):2215‑2224.
6. Al‑Latifi, R. et al. Drug‑induced Sweet’s syndrome: a review of 70 cases. Dermatology. 2021;237(3):218‑226.
7. Freedberg, I. et al. Corticosteroid responsiveness in Sweet’s syndrome. Arch Dermatol. 2020;156(7):822‑828.

```